Ascentage Pharma Group International
HKEX:6855

Watchlist Manager
Ascentage Pharma Group International Logo
Ascentage Pharma Group International
HKEX:6855
Watchlist
Price: 41.6 HKD 0.73%
Market Cap: 13B HKD
Have any thoughts about
Ascentage Pharma Group International?
Write Note

Ascentage Pharma Group International
Non-Reccuring Items

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ascentage Pharma Group International
Non-Reccuring Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Non-Reccuring Items CAGR 3Y CAGR 5Y CAGR 10Y
Ascentage Pharma Group International
HKEX:6855
Non-Reccuring Items
ÂĄ4k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Non-Reccuring Items
-ÂĄ248k
CAGR 3-Years
N/A
CAGR 5-Years
21%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Non-Reccuring Items
-ÂĄ23m
CAGR 3-Years
-439%
CAGR 5-Years
66%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Non-Reccuring Items
-ÂĄ222.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Non-Reccuring Items
-ÂĄ1.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Imeik Technology Development Co Ltd
SZSE:300896
Non-Reccuring Items
-ÂĄ106.9k
CAGR 3-Years
-2%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Ascentage Pharma Group International
Glance View

Market Cap
13.1B HKD
Industry
Biotechnology

Ascentage Pharma Group International Co., Ltd. develops and produces pharmaceutical products. The company is headquartered in Suzhou, Jiangsu and currently employs 613 full-time employees. The company went IPO on 2019-10-28. The firm focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The firm's main products include the next-generation kinase inhibitor: HQP1351 and apoptosis targeted drugs APG-1252, APG2575, APG-115 and so on. The firm conducts businesses within the domestic market and to overseas markets, including the United States.

Intrinsic Value
58.55 HKD
Undervaluation 29%
Intrinsic Value
Price

See Also

What is Ascentage Pharma Group International's Non-Reccuring Items?
Non-Reccuring Items
4k CNY

Based on the financial report for Dec 31, 2023, Ascentage Pharma Group International's Non-Reccuring Items amounts to 4k CNY.

What is Ascentage Pharma Group International's Non-Reccuring Items growth rate?
Non-Reccuring Items CAGR 1Y
-100%

Over the last year, the Non-Reccuring Items growth was -100%.

Back to Top